Spyre Therapeutics Inc SYRE
$106.49 $1.30 (1.21%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
SYRE Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Spyre Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Spyre Therapeutics Inc. Stock Analysis SYRE
United States Health Care Mid Cap Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
Spyre Therapeutics Inc (SYRE) Chart
Financial Metrics & Statements of Spyre Therapeutics Inc (SYRE)
FAQ's for Spyre Therapeutics Inc (SYRE)
- As of August 2026, Spyre Therapeutics Inc SYRE is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Spyre Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Spyre Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Spyre Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Spyre Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Spyre Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Spyre Therapeutics Inc (SYRE)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
